DR. TIMOTHY H BURGESS, M.D., M.P.H.
Osteopathic Medicine at Wisconsin Ave, Bethesda, MD
License number
Maryland 01044600
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Maryland 01044600
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
2
8901 Wisconsin Ave, Bethesda, MD 20889
503 Robert Grant Ave, Silver Spring, MD 20910
503 Robert Grant Ave, Silver Spring, MD 20910
Phone
(301) 319-7556
(301) 319-7451 (Fax)
(301) 319-7451 (Fax)
Personal information
See more information about TIMOTHY H BURGESS at radaris.comName
Address
Phone
5071 Green Bridge Rd, Dayton, MD 21036
Professional information
See more information about TIMOTHY H BURGESS at trustoria.com
Dr. Timothy H Burgess, Bethesda MD - MD (Doctor of Medicine)
Dr. Timothy H Burgess, Bethesda MD - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
8901 Wisconsin Ave, Bethesda 20889
(301) 319-7556 (Phone), (301) 319-7451 (Fax)
(301) 319-7556 (Phone), (301) 319-7451 (Fax)
Certifications:
Infectious Disease, 1999, Internal Medicine, 1997
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Indiana University / School of Medicine
Graduated: 1994
National Naval Medical Center
Nat Capitol Consortium
Indiana University / School of Medicine
Graduated: 1994
National Naval Medical Center
Nat Capitol Consortium
Timothy H Burgess, Bethesda MD
Timothy H Burgess, Bethesda MD
Specialties:
Infectious Disease Specialist
Address:
8901 Wisconsin Ave, Bethesda, MD 20889
503 Robert Grant Ave, Silver Spring, MD 20910
503 Robert Grant Ave, Silver Spring, MD 20910
Education:
Uniformed Services University of the Health Sciences - Master of Public Health
Indiana University, School of Medicine - Doctor of Medicine
Walter Reed Army Medical Center - Fellowship - Infectious Disease (Internal Medicine)
National Naval Medical Center - Residency - Internal Medicine
Indiana University, School of Medicine - Doctor of Medicine
Walter Reed Army Medical Center - Fellowship - Infectious Disease (Internal Medicine)
National Naval Medical Center - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Sub-certificate in Infectious Disease (Internal Medicine)
Method For The Evaluation Of Dengue Virus Therapeutic Agents
Method For The Evaluation Of Dengue Virus Therapeutic Agents
US Patent:
2008021, Sep 11, 2008
Filed:
Aug 21, 2006
Appl. No.:
11/507322
Inventors:
Timothy H. Burgess - Silver Spring MD, US
Kevin R. Porter - Boyds MD, US
Daniel A. Freilich - Washington DC, US
Denise L. Doolan - Camp Hill, AU
Kevin R. Porter - Boyds MD, US
Daniel A. Freilich - Washington DC, US
Denise L. Doolan - Camp Hill, AU
International Classification:
A61K 49/00
US Classification:
424 92
Abstract:
The inventive subject matter relates to a method for evaluating potential compounds and vaccines for the prevention or treatment of dengue virus infection. The method utilizes pigs as an animal model for the evaluation of test vaccine or drug compounds. The breeds that can be utilized and in the inventive method include Yorkshire or Lancashire as well as miniature pig breeds.
Dengue Virus Detection Measured By Immunocytometry In A Dendritic Cell Surrogate
Dengue Virus Detection Measured By Immunocytometry In A Dendritic Cell Surrogate
US Patent:
2007013, Jun 14, 2007
Filed:
Oct 26, 2006
Appl. No.:
11/586895
Inventors:
Timothy Burgess - Silver Spring MD, US
Jeffrey Tjaden - Eagle River AK, US
Kevin Porter - Boyds MD, US
Mary Marovich - Bethesda MD, US
Jeffrey Tjaden - Eagle River AK, US
Kevin Porter - Boyds MD, US
Mary Marovich - Bethesda MD, US
International Classification:
C12Q 1/70, C12Q 1/68
US Classification:
435006000, 435005000
Abstract:
The invention concerns a method for diagnosing dengue invention early after dengue virus infection. The method comprises binding dengue virus contained in sera from infected patients with dentritic cell-specific intracellular adhesion molecule (ICAM) 3-grabbing nonintegrin (DC-SIGN) or liver/lymph node-specific intracellular adhesion molecule (ICAM) 3-grabbing nonintegrin (L-SIGN). DC-SIGN or L-SIGN can be expressed in transfected B cells or adhered to other surfaces. Measurement of binding is by immunocytometry, microscopy or other antibody based methods.
Method For The Measurement Of Dengue Virus Binding Inhibition
Method For The Measurement Of Dengue Virus Binding Inhibition
US Patent:
2007013, Jun 14, 2007
Filed:
Oct 26, 2006
Appl. No.:
11/586894
Inventors:
Timothy Burgess - Silver Spring MD, US
Jeffrey Tjaden - Eagle River AK, US
Kevin Porter - Boyds MD, US
Nicole Martin - Olney MD, US
Mary Marovich - Bethesda MD, US
Jeffrey Tjaden - Eagle River AK, US
Kevin Porter - Boyds MD, US
Nicole Martin - Olney MD, US
Mary Marovich - Bethesda MD, US
International Classification:
C12Q 1/70, C12Q 1/68
US Classification:
435006000, 435005000
Abstract:
The invention concerns a method of detecting dengue infection by detecting anti-dengue neutralizing substances including anti-dengue antibody by measuring inhibition of dengue binding to dentritic cell-specific intracellular adhesion molecule (ICAM) 3-grabbing nonintegrin (DC-SIGN) or liver/lymph node-specific intracellular adhesion molecule (ICAM) 3-grabbing nonintegrin (L-SIGN). DC-SIGN or L-SIGN can be used expressed in transfected cell lines that normally are not infected by dengue virus. The invention also concerns a method of detecting anti-dengue drugs by their ability to inhibit binding of dengue virus to DC-SIGN or L-SIGN.